Loading company…
LyncBio Therapeutics develops antibody-drug conjugates for targeted therapies.
LyncBio Therapeutics develops antibody-drug conjugates (ADCs), including carriers, linkers and drug payloads for targeted therapies. Founded in 2023, it is based in Shanghai, China, and its research addresses oncology, inflammatory bowel disease and multiple sclerosis. In May 2026, it closed a Series A+ round from Apricot Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in